Scariya Kumaramangalam, MD
Psychiatry · Huntsville, ALNPI 1417996372
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $337,498 of the $440,222 with a category attached, or 76.7%. 35 manufacturers reported payments, led by AbbVie at 47.5% of the total. 2025 is the largest year on record at $105,498, 2.8 times the $37,719 reported in 2019. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,244 payments — averaging $353.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$209K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$118K
- Axsome Therapeutics, Inc.$72K
- Vanda Pharmaceuticals Inc.$27K
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $9K from 29 others
What the payments were for
- Consulting fees$60,55014%
- Speaking & faculty fees$337,49877%
- Travel & lodging$17,5974%
- Food & beverage$24,4366%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$204,304
- CAPLYTA$115,309
- Auvelity$70,309
- Fanapt$25,858
- ARISTADA$2,289
- LYBALVI$2,269
- LATUDA$700
- ARISTADA INITIO$572
- REXULTI$493
- ABILIFY MAINTENA$488
- SPRAVATO$427
- AUSTEDO$361
- INVEGA SUSTENNA$246
- Wegovy$246
- VIIBRYD$200
- Prolastin-C$142
- Jornay PM 20mg capsules (Bottle of 100)$139
- INVEGA TRINZA$138
- Azstarys$125
- NUEDEXTA$125
How this compares
$440,222 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 352 | $512,938 |
| CaplytaLumateperone Tosylate | 235 | $391,589 |
| NuedextaDextromethorphan Hbr/Quinidine | 55 | $83,108 |
| AuvelityDextromethorphan Hbr/Bupropion | 61 | $66,939 |
| RexultiBrexpiprazole | 25 | $35,788 |
| Abilify MaintenaAripiprazole | 17 | $35,718 |
| Aripiprazole | 667 | $31,206 |
| Oxcarbazepine | 862 | $29,502 |
| Invega SustennaPaliperidone Palmitate | 17 | $28,831 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 967 | $24,100 |
| BelsomraSuvorexant | 52 | $22,485 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,760 |
| TrintellixVortioxetine Hydrobromide | 20 | $18,200 |
| DayvigoLemborexant | 46 | $14,783 |
| Quetiapine Fumarate | 990 | $14,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $209,201 | $512,938352 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $118,080 | $391,589235 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $530 | $83,10855 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,829 | $71,50642 claims |
| Axsome Therapeutics, Inc.Auvelity | $72,188 | $66,93961 claims |
| Johnson & JohnsonInvega Sustenna | $1,422 | $28,83117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $218 | $24,62737 claims |
| MerckBelsomra | $21 | $22,48552 claims |
| Alkermes, Inc.Lybalvi | $2,793 | $20,76014 claims |
| Eisai Inc.Dayvigo | $61 | $14,78346 claims |
| Lilly USA, LLCOlanzapine | $125 | $5,869474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Huntsville
- Glenn ArchibaldHuntsville$24K
- Sofia AeschlimannHuntsville$18K
- Heath PenlandHuntsville$11K
- Quratulain AghaHuntsville$10K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.